Teva Pharmaceutical has agreed to a $1.2 billion settlement to resolve anti-competition charges over sales of its popular Provogil sleep-disorder drug.
The settlement comes from a 2008 Federal Trade Commission lawsuit in which the FTC accused Cephalon, which was acquired by Teva in 2012 — of illegally protecting its market monopoly on Provigil through a series of agreements with four generic drug manufacturers.
According to the settlement terms, Teva will make the money available to compensate drug wholesalers, pharmacies and insurers who overpaid for Provogil.
Read the USA Today article